Search clinical trials for: Toripalimab and Anlotinib

Total 272175 results

Sun Yat-sen University

Recruiting

Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma

Sarcoma,Soft Tissue

China
Qilu Hospital of Shandong University

Not yet recruiting

Toripalimab Combined With Anlotinib in Unresectable Locally Advanced or Metastatic Acral Malignant Melanoma

Locally Advanced or Metastatic Acral Malignant Melanoma

China
Sun Yat-sen University

Active, not recruiting

Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)

Nasopharyngeal Carcinoma | Recurrent or Metastatic Nasopharyngeal Carcinoma

China
Shanghai Changzheng Hospital

Unknown

Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric or Gastro-esophageal Junction Cancer (APICAL-GE)

Gastric Cancer | Immunotherapy | Anlotinib | Toripalimab | Gastro-oesophageal Junction Cancer

China
Taizhou Hospital

Not yet recruiting

Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell (SCLC)

SCLC | Maintenance Treatment
Shen Feng

Recruiting

Clinical Recruitment of Patients With First-line Targeted Drug Resistance or Intolerance to Hepatocellular Cancer With PD-1 Inhibitor (Toripalimab,JS001) Detected on the NGS Platform Combined With Anlotinib

Hepatocellular Cancer

China
Henan Cancer Hospital

Unknown

Anrotenib Plus Toripalimab Versus Toripalimab in Patients With Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma
Hubei Cancer Hospital

Recruiting

Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC

NSCLC

China
Third Military Medical University

Recruiting

Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer

Small Cell Lung Cancer | Lung Cancer | SCLC, Extensive Stage

China
Di Wu

Not yet recruiting

Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma

Undifferentiated Pleomorphic Sarcoma | Soft Tissue Sarcomas

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)

Non Small Cell Lung Cancer Recurrent
Cancer Institute and Hospital, Chinese Academy...

Unknown

To Evaluate the Efficacy and Safety of Anlotinib Combined With Allitinib in Lung Cancer

Lung Cancer
Xijing Hospital

Not yet recruiting

Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma

Melanoma

China
Tianjin Medical University Cancer Institute and...

Recruiting

Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer

Non-small-cell Lung Cancer

China
RemeGen Co., Ltd.

Recruiting

RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC

NSCLC

China
Sun Yat-sen University

Not yet recruiting

ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC (CONTINUE)

Lung Cancer, Nonsmall Cell
Nanfang Hospital, Southern Medical University

Not yet recruiting

Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma

Neoadjuvant Therapy | Esophageal Carcinoma
Taizhou Hospital

Not yet recruiting

First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC

Small Cell Lung Carcinoma

China
Coherus Biosciences, Inc.

Not yet recruiting

A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors
Fujian Cancer Hospital

Unknown

EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC

EGFR Gene Mutation

China
Shanghai Chest Hospital
Allist Pharmaceuticals, Inc.

Recruiting

Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC (FOCUS-A)

Non-Small-Cell Lung Cancer

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Not yet recruiting

9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer

Advanced Urothelial Carcinoma

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Anlotinib, Toripalimab and Nab-paclitaxel in Locally Advanced/Metastatic Pancreatic Cancer (ATNPA)

Locally Advanced Pancreatic Adenocarcinoma | Metastatic Pancreatic Cancer | Pancreatic Neoplasm

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Study to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer Patients

Advanced Solid Tumors

China
Sun Yat-sen University

Recruiting

Chidamide Combined With Toripalimab in Sarcoma

Sarcoma

China
Peking Union Medical College Hospital

Recruiting

A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL

Pheochromocytoma | Paraganglioma

China
Peking Union Medical College Hospital

Recruiting

The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma

Paraganglioma, Extra-Adrenal | Malignant Adrenal Gland Pheochromocytoma | Malignant Paraganglioma | Pheochromocytoma, Metastatic | Paraganglioma, Malignant

China
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

AK105 Combined With Anlotinib in Patients With Cervical Cancer

Cervical Cancer
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Toripalimab Therapy After Resection in High-risk Stage IA2-IB NSCLC With no Driver Alterations (EGFR or ALK)

NSCLC
Qianfoshan Hospital

Recruiting

A Real-World Study of Toripalimab in Chinese Patients With Lung Cancer(THUNDER Study)

Lung Cancer

China
RemeGen Co., Ltd.

Recruiting

A Study of RC118 Plus Toripalimab in Patients With Locally Advanced Unresectable or Metastatic Solid Tumors

Advanced Solid Tumor

China
Sun Yat-sen University
The First Affiliated Hospital of Guangzhou Medical University; Guangzhou Panyu...

Recruiting

Study of Toripalimab for Limited-Stage Small Cell Lung Cancer Following Concurrent Chemoradiotherapy

Small Cell Lung Cancer Limited Stage

China
Ruijin Hospital

Recruiting

Combination Therapy for First Line Treatment of Advanced Cervical Cancer

Advanced Cervical Cancer

China
Sun Yat-sen University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Maintenance Treatment for Advanced Soft Tissue Sarcoma

Soft Tissue Sarcoma

China
First Hospital of Shijiazhuang City

Unknown

Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLC

Carcinoma | Small Cell Lung Cancer | Lung Neoplasm

China
Henan Cancer Hospital

Recruiting

Teripalimab Plus Chemotherapy in Local Advanced Esophageal Cancer

Esophageal Cancer | Squamous Cell Carcinoma | Perioperative Period

China
Canwell Biotech Limited

Not yet recruiting

CAN1012 Combined With PD-1 in Patients With Solid Tumors

Advanced Solid Tumor

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

A Study of Toripalimab as Consolidation Therapy After Postoperative Chemoradiotherapy in HNSCC

Head and Neck Squamous Cell Carcinomas

China
Shanghai Junshi Bioscience Co., Ltd.

Not yet recruiting

Intensive Medicines Monitoring Study of Toripalimab Monoclonal Injection (Tuoyi) .

Melanoma | Breast Cancer | Lung Cance

China
Zhejiang Genfleet Therapeutics Co., Ltd.

Completed

A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China, Australia
Fudan University

Unknown

Toripalimab in the Neoadjuvant Treatment of BRAF V600 Wild Type Melanoma (FU-Name-T001)

Melanoma Stage IIIB-IV

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

Limited-stage Small Cell Lung Cancer (LS-SCLC)

China, France, United States, Spain, Taiwan, Korea, Republic of, Turkey, Italy, Netherlands, Georgia, Germany, Belgium, Poland, Romania
First People's Hospital of Hangzhou
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study of Anlotinib in the Treatment of Recurrent High-grade Glioma

Recurrent High-grade Glioma

China
Peng Yuan

Completed

Anlotinib in Metastatic HER2 Negative Breast Cancer

Breast Neoplasm | Antineoplastic Agents | Anlotinib

China
Guangzhou Institute of Respiratory Disease
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance

IIIb/IV NSCLC With T790M Positive Mutations Failed to Osimertinib Therapy

China
Peking Union Medical College Hospital
Chineo Medicine (Beijing) Co., Ltd.

Not yet recruiting

Clinical Study on the Safety, Pharmacokinetics, and Efficacy of ScTIL (Genetically Modified Tumor Infiltrating Lymphocytes) in the Treatment of Gynecological Malignancies

Cervical Cancer | Ovarian Cancer | Malignant Trophoblastic Tumor
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of Toripalimab Injection in the Treatment of Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy and Are Positive Specific Markers

Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy

China
Hunan Cancer Hospital
Henan Cancer Hospital; Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors

Non Small Cell Lung Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031)

Medullary Thyroid Carcinoma

China
Guangdong Association of Clinical Trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

NSCLC

China

3

Subscribe